Abstract: The invention relates to a chewing gum comprising at least a gum core comprising nicotine polacrilex, at least a one outer coating covering the core, comprising at least one sugar alcohol or mixtures of sugar alcohols and, at least a one portion fused onto the outer coating, wherein the portion comprises nicotine bitartrate or nicotine ditartrate dihydrate and at least one sugar alcohol or a mixture of sugar alcohols and at least one buffer present in the coating and/or in a portion fused to the coating.

Abstract: This invention relates to a nicotine chewing gum giving an immediate release and uptake of nicotine and an extended release and uptake of nicotine as well as describing suitable manufacturing processes for such chewing gum formulations and the use of the chewing gum for the treatment of a human being suffering from cravings from tobacco and/or e-cigarette dependency.

Abstract: The invention relates to a nicotine chewing gum giving an immediate release and uptake of nicotine as well as an extended release and uptake of nicotine as well as describing suitable manufacturing processes for such chewing gum formulations and the use of the chewing gum for the treatment of a human being suffering from cravings from tobacco and/or e-cigarette dependency.

Abstract: This invention relates to a nicotine lozenge giving an immediate release and uptake of nicotine and an extended release and uptake of nicotine as well as describing suitable manufacturing processes for such lozenge formulations and the use of the lozenge for the treatment of a human being suffering from cravings from tobacco and/or e-cigarette dependency.

Abstract: The invention relates to a lozenge comprising micronized benzocaine, at least one dissolution enhancer and one or more excipients as well as the use of the lozenge for the treatment of sore throat.

Abstract: The invention relates to a lozenge comprising micronized benzocaine, at least one dissolution enhancer and one or more excipients as well as the use of the lozenge for the treatment of sore throat.

Abstract: The invention relates to a chewing gum comprising at least a gum core comprising nicotine polacrilex, at least a one outer coating covering the core, comprising at least one sugar alcohol or mixtures of sugar alcohols and, at least a one portion fused onto the outer coating, wherein the portion comprises nicotine bitartrate or nicotine ditartrate dihydrate and at least one sugar alcohol or a mixture of sugar alcohols and at least one buffer present in the coating and/or in a portion fused to the coating.

Abstract: The invention relates to a lozenge comprising micronized benzocaine, at least one dissolution enhancer and one or more excipients as well as the use of the lozenge for the treatment of sore throat.

Abstract: Solid pharmaceutical dosage form for the release of at least one Active Pharmaceutical Ingredient (API) in the oral cavity comprising a core coated by at least one film coating. The core comprises at least one API. One or more organoleptically disturbing sensations induced by one or several of the APIs and/or of inactive components of the solid pharmaceutical dosage form is/are reduced by constituents of said film coating. Said constituents comprise at least one film-forming polymer and at least one flavoring agent or at least one sweetener.

Abstract: Solid pharmaceutical dosage form for the release of at least one Active Pharmaceutical Ingredient (API) in the oral cavity comprising a core coated by at least one film coating. The core comprises at least one API. One or more organoleptically disturbing sensations induced by one or several of the APIs and/or of inactive components of the solid pharmaceutical dosage form is/are reduced by constituents of said film coating. Said constituents comprise at least one film-forming polymer and at least one flavoring agent or at least one sweetener.

Abstract: Provided are liquid pharmaceutical formulations comprising nicotine in any form for administration essentially to the lungs being acidified and/or alkalized by buffering and/or pH regulation providing for a tmax of nicotine in arterial blood of a subject within a short period of time after administration. The administration is preferably accomplished by spraying an aerosol into the oral cavity for further distribution essentially into the lungs. Methods for manufacturing the formulation is also disclosed, as are uses of the formulation in therapy, such as therapy for treating addiction to tobacco.

Abstract: Solid pharmaceutical dosage form for the release of nicotine in the oral cavity comprising a core encapsulated by at least one film coating, wherein the core comprises nicotine and wherein the film coating comprises at least one film-forming polymer and at least one component for reduction of one or more organoleptically disturbing sensations, and where the at least one film coating is devoid of nicotine and devoid of buffer.

Abstract: Provided are liquid pharmaceutical formulations comprising nicotine in any form for administration essentially to the lungs being acidified and/or alkalized by buffering and/or pH regulation providing for a tmax of nicotine in arterial blood of a subject within a short period of time after administration. The administration is preferably accomplished by spraying an aerosol into the oral cavity for further distribution essentially into the lungs. Methods for manufacturing the formulation is also disclosed, as are uses of the formulation in therapy, such as therapy for treating addiction to tobacco.

Abstract: A multi portion intra-oral dosage form has at least one pharmaceutically active agent or health promoting agent with at least one portion comprises a component for creating a noticeable organoleptic sensation. The sensory markers or signals are conceptual aids for a subject using the dosage form where the organoleptic sensation is such that it facilitates the subject to identify a portion and differentiate between different portions. Also contemplated are a dosage form, a method and a system for delivering active agents, such as nicotine and/or metabolites thereof, such as cotinine, nicotine N?-oxide, nomicotine, (S)-nicotine-N-?-glucuronide and mixtures, isomers, salts and complexes thereof as well as use and production of said dosage forms.

Abstract: A pharmaceutical formulation comprising one or more active pharmaceutical ingredients (APIs) suitable for intraoral uptake, that comprises cocoa powder, a process for manufacturing the formulation and use of the formulation for medical treatment.

Abstract: A liquid pharmaceutical formulation comprising nicotine in any form for administration essentially to the lungs being acidified and/or alkalized by buffering and/or pH regulation providing for a tmax of nicotine in arterial blood of a subject within a short period of time after administration. The administration is preferably by spraying an aerosol into the oral cavity for further distribution essentially into the lungs. A method for manufacturing said formulation. Use of said formulation in therapy, such as therapy for treating addiction to tobacco.

Abstract: The present invention relates to a multi portion intra-oral dosage form where at least one portion is rapidly disintegrating and at least one portion is slowly disintegrating, whereby the disintegration time for the slowest disintegrating portion is at least two times longer than for the most rapidly disintegrating portion. Of certain interest is use of sensory markers/signals as conceptual aids for the subject. Also contemplated are a method and a system for delivering active agents, such as nicotine and/or metabolites thereof, such as cotinine, nicotine N?-oxide, nornicotine, (S)-nicotine-N-?-glucuronide and mixtures, isomers, salts and complexes thereof as well as use and production of said formulations.

Abstract: The present invention provides for a sexual dysfunction compound comprising a rapid-onset pharmaceutical composition that further comprises cocoa powder. The invention also provides for a process for manufacturing the composition, and use of the composition in sexual dysfunction therapy.

Abstract: Devices for transdermal administration of nicotine, which provide for basic as well as additional user activatable administration of nicotine, as well as use of such devices.

Abstract: A pharmaceutical formulation comprising one or more active pharmaceutical ingredients (APIs) suitable for intraoral uptake, that comprises cocoa powder, a process for manufacturing the formulation and use of the formulation for medical treatment.